Topics

PubMed Journals Articles About "Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth" RSS

10:33 EST 17th January 2020 | BioPortfolio

Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth articles that have been published worldwide.

More Information about "Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth" on BioPortfolio

We have published hundreds of Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth news stories on BioPortfolio along with dozens of Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth Clinical Trials and PubMed Articles about Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth Companies in our database. You can also find out about relevant Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth Drugs and Medications on this site too.

Showing "Atopic Dermatitis Therapeutics Southeast Asia Markets 2024 Growth" PubMed Articles 1–25 of 13,000+

Efficacy and Safety of Oral Janus Kinase 1 Inhibitor Abrocitinib for Patients With Atopic Dermatitis: A Phase 2 Randomized Clinical Trial.

Atopic dermatitis is associated with substantial patient and caregiver burden. Currently available treatments for atopic dermatitis are inadequate or contraindicated for some patients. Abrocitinib (PF-04965842) is an oral Janus kinase 1 selective inhibitor under investigation for the treatment of atopic dermatitis.


Psoriasis-Like Dermatitis Developing in an Atopic Dermatitis Patient Treated With Dupilumab.

Tocopherol Allergic Dermatitis Masquerading as Lifelong Atopic Dermatitis.


The Association Between Mercury Exposure and Atopic Dermatitis in Early Childhood: A Mothers and Children's Environmental Health Study.

Atopic dermatitis is a chronic and relapsing inflammatory skin disease. Although mercury has been suggested as a risk factor, the underlying mechanism and the relationship between mercury and atopic dermatitis remains unclear. The objective of the present study was to investigate the relationship between mercury exposure and the presence of atopic dermatitis in early childhood.

I. inflexus (Thunb.) Kudo extract improves atopic dermatitis and depressive-like behavior in DfE-induced atopic dermatitis-like disease.

Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disease, which is caused by several genetic, immunological, and environmental factors. In addition to skin manifestations, AD is associated with an increased risk of depression and suicidal ideation. Furthermore, this association is underappreciated and therefore insufficiently studied.

How does parental history of atopic disease predict the risk of atopic dermatitis in a child? - a systematic review and meta-analysis.

Parental history of atopic disease is a well-established risk factor for development of atopic dermatitis (AD), but several aspects of this association remain unclear.

Atopic Dermatitis Score 7 (ADS7): a promising tool for daily clinical assessment of atopic dermatitis.

Dupilumab in Dermatology: Potential for Uses Beyond Atopic Dermatitis

Dupilumab inhibits the interleukin-4 receptor subunit α and is FDA approved for treatment of moderate-to-severe atopic dermatitis. It is a relatively new drug, and whether it is efficacious for other diseases in dermatology is an area of increasing interest. We searched the literature and ClinicalTrials.gov database for uses of dupilumab beyond atopic dermatitis in dermatology and for ongoing studies on new uses for dupilumab. Off-label reports identified described use of dupilumab for several different de...

Successful Use of Dupilumab for Recalcitrant Atopic Dermatitis in an HIV Patient.

Maternal and paternal atopic dermatitis and risk of atopic dermatitis during early infancy in girls and boys.

Omalizumab as an adjuvant therapy for treating severe atopic dermatitis in children. A serie of cases.

Atopic dermatitis (AD) is a chronic skin disease that affects 5-20% of children. This disease compromises the quality of life. Omalizumab offers a promising role in the treatment of severe atopic dermatitis.

A Rare Case of Lichen Planus-Like Atopic Dermatitis Involving the Hands.

Lichen planus-like atopic dermatitis clinically mimics lichen planus and can pose a diagnostic challenge. We report a case of a 55-year-old African American woman who developed intensely pruritic papules and plaques on bilateral hands. Histological examination demonstrated acute spongiotic dermatitis with lymphocyte exocytosis into the epidermis. Taken together, a diagnosis of lichen planus-like atopic dermatitis was made. This case serves to highlight that lichen planus-like atopic dermatitis can develop o...

Novel therapies based on the pathophysiology of atopic dermatitis.

Our understanding of the mechanisms underlying atopic dermatitis has been instrumental in the development of novel pharmacological agents. Worldwide, more than seventy companies are currently developing at least one new drug for the treatment of atopic dermatitis. Based on our current understanding of the pathophysiology of the disease, the present review article highlights the most important novel therapeutic strategies.

Validation of the Patient-Oriented SCORing for Atopic Dermatitis (PO-SCORAD) for black skin.

SCORing for Atopic Dermatitis (SCORAD) is a tool developed by the European Task Force on Atopic Dermatitis which is used by physicians to assess atopic dermatitis (AD) severity during consultations with their patients. Patient-Oriented SCORAD (PO-SCORAD) is a self-assessment tool for use by patients which has been validated in a study performed in European countries. However, there is currently no adapted tool for evaluating AD severity in black skin.

Clinical characteristics, symptoms, and burden of psoriasis and atopic dermatitis in adults.

There is debate whether psoriasis and atopic dermatitis (AD) belong to the same disease spectrum.

Patch Test Results of Contact Sensitization in Children Without Atopic Dermatitis: A Single Tertiary Center Experience.

Allergic contact dermatitis (ACD) has become more frequent in children. The prevalence of contact sensitization varies with respect to age, sex, and geographic localization.

ATOPIC DERMATITIS AS A PRIMARY EPIDERMAL DISEASE: CLINICAL IMPLICATIONS.

Atopic dermatitis (AD) is one of the most common inflammatory skin diseases in the western world. Multiple causes have been implicated in the pathogenesis of atopic dermatitis, however in the past years many studies have highlighted the pathogenic role played by abnormal skin barrier in patients with AD. Impaired skin barriers facilitate the penetration of environmental agents/allergens into the skin with resultant chronic inflammation and atopic march. Many components of the epidermal barrier are impaired ...

Predicting skin barrier dysfunction and atopic dermatitis in early infancy.

Dry skin, associated with increased transepidermal water loss (TEWL), is found to precede atopic dermatitis (AD) in childhood.

What is the evidence for interactions between filaggrin null mutations and environmental exposures in the aetiology of atopic dermatitis? - A systematic review.

Epidemiological studies indicate that gene-environment interactions play a role in atopic dermatitis.

Interleukin-32γ suppressed atopic dermatitis through inhibition of miR-205 expression via inactivation of nuclear factor-kappa B.

Interleukin 32 (IL-32) is a novel cytokine involved in many inflammatory diseases. However, the role of IL-32γ, an isotype of IL-32, in atopic dermatitis has not been reported.

Validation of four single-item patient-reported assessments of sleep in adult atopic dermatitis patients: Sleep in atopic dermatitis.

The optimal approaches for monitoring sleep disturbances in adults with atopic dermatitis (AD) is not established. Multiple patient-reported outcome measures for AD and itch have sleep-related items. These items have not been validated previously.

Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis: A Randomized Clinical Trial.

The dupilumab regimen of 300 mg every 2 weeks is approved for uncontrolled, moderate to severe atopic dermatitis (AD).

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial.

Atopic dermatitis is a chronic inflammatory skin disease characterized by pruritic skin lesions.

Association of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis.

Atopic dermatitis (AD) is a common chronic illness that has been associated with variation in the filaggrin gene (FLG). Four variants are most often evaluated.

Evolution of pathologic T-cell subsets in atopic dermatitis from infancy to adulthood.

The circulating immune phenotype was defined in adults and young children with early atopic dermatitis/AD, but chronologic changes in blood of AD infants and children through adolescence have not been explored.


Quick Search